Ontology highlight
ABSTRACT:
SUBMITTER: Nathanson KL
PROVIDER: S-EPMC3924894 | biostudies-literature | 2013 Sep
REPOSITORIES: biostudies-literature
Nathanson Katherine L KL Martin Anne-Marie AM Wubbenhorst Bradley B Greshock Joel J Letrero Richard R D'Andrea Kurt K O'Day Steven S Infante Jeffrey R JR Falchook Gerald S GS Arkenau Hendrik-Tobias HT Millward Michael M Brown Michael P MP Pavlick Anna A Davies Michael A MA Ma Bo B Gagnon Robert R Curtis Martin M Lebowitz Peter F PF Kefford Richard R Long Georgina V GV
Clinical cancer research : an official journal of the American Association for Cancer Research 20130705 17
<h4>Purpose</h4>Dabrafenib is a selective inhibitor of V600-mutant BRAF kinase, which recently showed improved progression-free survival (PFS) as compared with dacarbazine, in metastatic melanoma patients. This study examined potential genetic markers associated with response and PFS in the phase I study of dabrafenib.<h4>Experimental design</h4>Baseline (pretreatment or archival) melanoma samples were evaluated in 41 patients using a custom genotyping melanoma-specific assay, sequencing of PTEN ...[more]